Keymed Biosciences gibt die IND-Genehmigung für CM518D1 durch die National Medical Products Administration of China zur Behandlung von Solide Tumoren bekannt ...Middle East

CHENGDU, China, 27. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) („Keymed" oder das „Unternehmen") gab vor kurzem bekannt, dass CM518D1, ein von Keymed entwickeltes Antikörper-Wirkstoff-Konjugat (ADC), das auf CDH17 abzielt, vom Center for Drug Evaluation (CDE) der...

Hence then, the article about keymed biosciences gibt die ind genehmigung fur cm518d1 durch die national medical products administration of china zur behandlung von solide tumoren bekannt was published today ( Sunday 27/04/2025 - 07:13 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences gibt die IND-Genehmigung für CM518D1 durch die National Medical Products Administration of China zur Behandlung von Solide Tumoren bekannt )

Also on site :

• Crews respond to large fire at Denny Hamlin's parents' house in Stanley: Sources
• Reported tornado rips roofs off multiple homes in central Illinois
• Heidi Klum ditches bikini top to cozy up to husband Tom Kaulitz during St. Barths vacation